Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04983745
Title Niraparib and Dostarlimab in HRD Solid Tumors (DIDO)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors West Cancer Center

Advanced Solid Tumor


Dostarlimab-gxly + Niraparib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST